Quick Answer
AbCellera Biologics Inc. reported Cash and Equivalents of $61.80 million for fiscal year 2025.
AbCellera Biologics Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $61.80M | +11.2% |
| 2024 | $55.60M | -58.3% |
| 2023 | $133.32M | +196.9% |
| 2022 | $44.90M | +447.6% |
| 2021 | $8.20M | -98.6% |
| 2020 | $594.12M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $83.16M | -34.3% | -10.0% |
| June 30, 2025 | $92.44M | -37.7% | -42.0% |
| March 31, 2025 | $159.27M | +28.9% | +1.9% |
| December 31, 2024 | $156.32M | +17.3% | +23.4% |
| September 30, 2024 | $126.64M | -26.6% | -14.6% |
| June 30, 2024 | $148.31M | -17.5% | +20.0% |
| March 31, 2024 | $123.57M | -36.0% | -7.3% |
| December 31, 2023 | $133.32M | -65.5% | -22.7% |
- AbCellera Biologics Inc. showed an increase of +11.2% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, AbCellera Biologics Inc.’s cash and equivalents has declined by 89.6% (from $594.12 million to $61.80 million).
- The most recent figure is from AbCellera Biologics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: